Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured Article from MarketBeat.com 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. If you're considering the small-cap biotech sector, patience is a necessity. Most of these companies remain in the clinical stage and do not yet have commercially available drugs or therapeutics. That also means negative earnings (they are not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. While market uncertainty could send some of America's most popular stocks crashing down even further in 2026 …
This secret has identified three under-the-radar picks that could thrive in 2026 and beyond.
To learn their names and ticker symbols for FREE … Click here NOW — before it's too late. Even if a product advances through trials, profitability can still be years away. Only after reaching that milestone do companies typically receive the analyst coverage that attracts institutional investment. Getting in early on one of these medical stocks and watching it succeed can feel like hitting the lottery: returns of 3x, 5x, or even 10x are possible. Many other names will never pan out, which is why investors who trade penny stocks often spread a lump sum across many biotech companies. If it's a numbers game, diversification can be an effective strategy. With that in mind, here are two small-cap biotech stocks that carry significant risks but also offer the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular-diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in this space, Mainz Biomed already has a commercial product: ColoAlert — the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany's digital-health pioneers. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is meaningful. Mainz Biomed is also developing a non-invasive blood-based screening test for early detection of pancreatic cancer and reported positive topline results in October. Commercial approval for that test, however, remains years away. Still, the risks are substantial. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, revenue remains limited. The company included “Going Concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed filed a $150 million mixed shelf offering, which has helped keep MYNZ above $1 and avoid a delisting notice for now. Mainz Biomed needs to generate meaningful revenue to change its trajectory; if it succeeds, even a small investment could produce a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech pursuing a potentially disruptive approach to antivirals—and it carries the financial risks that speculative investors should weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary "nanoviricide" platform. These drug candidates are designed to mimic human cell surfaces and lure viruses into binding with them, effectively neutralizing the pathogens before they can infect real cells. If validated in human trials, the approach could represent a new method for treating infectious diseases. NanoViricides' pipeline includes candidates aimed at shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced, with encouraging preclinical data that suggest strong antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and dependent on fresh capital to continue development. The company reported limited cash on hand in recent filings, so investors should expect the possibility of future dilution. Still, if even one candidate advances successfully into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC is a genuine moonshot in the antiviral space.
| 
